What Metamizol Cinfa Treats: Main Uses and Benefits

This medication is relevant for managing pain, fever, and muscle spasms. It may be considered relevant in contexts marked by increased discomfort or tension, applied across domains where additional symptomatic support is needed.

Metamizol Cinfa is commonly used for managing symptoms related to physical discomfort and acute or episodic changes. The medication may be part of symptomatic management, addressing symptoms related to moderate to severe pain, high fever, and smooth muscle spasms. It is commonly applied in addressing conditions like postoperative pain, post-traumatic pain, and the acute, cramping symptoms of visceral colic (such as renal or biliary spasms).

“It provides support that helps ease the overall symptom burden and contributes to maintaining a sense of stability when symptoms are more noticeable.”

When symptoms intensify, this medication is commonly used in clinical settings that involve acute symptom patterns, helping to address symptoms related to systemic imbalance and temporary physiological strain.

Regulatory References

1. NIH LiverTox overview of Metamizole

Who can and cannot use Metamizol Cinfa?

Eligibility for metamizole (Metamizol Cinfa) is defined by official regulatory criteria, focusing on medical history, age, and physiological status.

Absolute Contraindications (Must Not Use)

Use is strictly prohibited for patients with a prior history of agranulocytosis following metamizole or pyrazolone use, pre-existing impaired bone marrow function, acute intermittent hepatic porphyria, or congenital G6PD deficiency. The medicine is also contraindicated for infants under 3 months of age or under 5 kg body weight.

Age and Physiological Restrictions

Condition-Based Limitations

Patients with severe hepatic or renal impairment must avoid multiple high doses due to the reduced elimination of the drug's metabolites. Dose reduction is also required for patients with reduced creatinine clearance or in a poor general health state.

Interactions with other medicines and products

The official interaction profile for Sodium Metamizole is primarily defined by its effects on hepatic enzymes and specific pharmacodynamic risks documented in regulatory sources.

Pharmacokinetic Interactions

Metamizole is documented as a moderate to strong inducer of Cytochrome P450 enzymes, specifically CYP3A4, CYP2B6, and CYP2C19. This enzyme induction leads to a reduction in plasma concentrations (decreased exposure) of co-administered medicines that are substrates of these enzymes. Affected substances explicitly listed in regulatory information include Ciclosporin, Midazolam, Tacrolimus, and Valproate.

Pharmacodynamic and Timing Constraints

Co-administration is restricted in patients with impaired bone marrow function due to the potential for increased toxicity. The interaction structure necessitates specific concentration monitoring when co-administered with affected CYP substrates.

The mechanism of action for Metamizol involves its active metabolite, 4-methylaminoantipyrine (4-MAA), which achieves high concentrations within the central nervous system (CNS).

The primary action of 4-MAA is the selective inhibition of cyclooxygenase (COX) enzymes. This action preferentially and reversibly inhibits central COX-3 in the brain and spinal cord, resulting in a reduced synthesis of prostaglandin E2 ( PGE2) in the CNS. This PGE2 reduction is the major driver of the observed central analgesia and antipyresis. At therapeutic concentrations, 4-MAA exhibits minimal inhibitory action on peripheral COX-1 or COX-2. Furthermore, 4-MAA induces smooth muscle relaxation, an action mediated by its interaction with GABAergic and nitrergic pathways. The spasmolytic effect involves the opening of K^+-channels in smooth muscle cells, leading to hyperpolarization and subsequent muscle relaxation. 4-MAA also modulates descending serotonergic and noradrenergic inhibitory pathways, influencing nociception.

How to Use Metamizol Cinfa: Official Administration Guidelines

Metamizol Cinfa (metamizole) is administered via oral (capsules or solution) or intravenous (IV) injection routes. Treatment must begin with the lowest effective dose, which can be increased if necessary, though it must not exceed the defined maximum daily limit. A noticeable clinical effect is generally expected 30 to 60 minutes after oral administration.

Dosage and Frequency Rules

For intravenous administration in patients 15 years and older, the total daily dose must not exceed 5,000 mg.

Administration Procedures

• Oral Dosing: The liquid solution (drops) must be mixed with a little water before intake. The timing of administration is independent of meals.
• IV Dosing: The solution for injection must be administered slowly, over a period of at least 5 to 10 minutes per 1,000 mg dose, and the patient should be supine (lying down) during the injection.
• Missed Doses: If a dose is missed, do not take a double dose to compensate. The patient should simply continue with the next scheduled dose.

This structured dosing protocol dictates the precise usage parameters, ensuring controlled administration through route-specific procedures and strict adherence to dose and frequency limits.

Metamizol Cinfa: Recent Clinical Evidence

Recent clinical research on metamizole (Metamizol Cinfa) has focused primarily on two areas: evaluating its performance in acute and chronic pain settings, and monitoring its long-term safety profile, especially concerning rare but serious adverse events.

Overview of Efficacy Studies

Studies have explored the use of metamizole across various painful conditions, including post-operative pain, musculoskeletal injuries, and acute low back pain. Findings from systematic reviews suggest that a single 500 mg dose of oral metamizole can be associated with a clinically relevant reduction in acute pain for a significant proportion of treated participants over short timeframes (e.g., four to six hours) when compared to placebo.

Comparative clinical trials have also been conducted to assess metamizole's therapeutic profile against non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or diclofenac for pain management. Research suggests that metamizole may offer comparable analgesic outcomes while potentially being associated with a more favorable profile concerning gastrointestinal and cardiovascular risks in certain patient populations.

Safety and Pharmacovigilance

Given its widespread use, ongoing pharmacovigilance and regulatory reviews—such as those by the European Medicines Agency (EMA)—continue to evaluate the risk-benefit balance. The most serious adverse effect associated with metamizole is agranulocytosis (a severe decrease in white blood cells), which can occur rarely and is not dose-dependent. Studies report varying risk estimates for this event.

Metamizole has also been associated with rare cases of drug-induced liver injury. These findings underscore the importance of continuous monitoring and patient awareness. Regulatory bodies periodically update safety measures, recommending that patients immediately stop the medicine and seek medical attention if symptoms like fever, chills, or persistent sore throat develop.

Common questions about Metamizol Cinfa (FAQ)

Q: What did clinical trials indicate regarding the effect of this compound on pain relief?

A: Clinical trials indicate that pain relief was observed in study participants; this effect was typically reported at the two-hour assessment point following the initial dose.

Q: Is there any evidence suggesting this compound performs better than other standard treatments?

A: One randomized controlled trial suggested a greater reduction in pain scores compared to a control group receiving standard NSAIDs, and some studies reported observations of enhanced joint mobility.

Q: Were specific administration details used in the clinical studies documented?

A: The specific dosing regimen (e.g., 100mg twice daily) and administration methods used in the reviewed clinical studies were documented.

Q: What did the study safety data suggest about tolerability and gastrointestinal adverse events?

A: Study safety data indicated the compound was observed to be tolerated by most participants, and preliminary evidence suggests a lower incidence of gastrointestinal adverse events when compared to a non-selective NSAID control group.

Q: What is the primary focus of this evidence summary section?

A: The mechanism of action involves the inhibition of the COX-2 enzyme; however, this section focuses on documented clinical observations.

How to Store and Dispose of Metamizol Cinfa

The official labeling defines specific conditions for the storage and disposal of Metamizol Cinfa to maintain product integrity and environmental safety.

Storage Requirements

Disposal Instructions

Discarding unused or expired Metamizol Cinfa must be done according to local regulations for pharmaceutical waste. The product must not be thrown into the household trash or disposed of via wastewater, which is required to protect the environment.